OTCM
ALID
Market cap1mUSD
Dec 03, Last price
0.01USD
1D
0.00%
IPO
-99.11%
Name
Allied Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Allied Corp., a medical cannabis production company, engages in the research, development, and production of cannabinoid health solutions in the United States. It offers hemp-derived natural health products, including Liberty, a hemp-derived cannabidiol (CBD) tincture; Tactical Hydration, a CBD infused electrolyte replacement drink; FIZZ Tablets for adding in a water bottle; Battle Balm, a CBD roll on activity rub for aches and pains; and Quick Hit, a CBD gummy under the Tactical Relief brand. The company also provides Hydrosport CBD Drink, a CBD infused electrolyte replacement drink with sodium citrate electrolyte replacement; Hydrosport Tincture, a CBD tincture fortified with specific terpene profile; FIZZ Tablets for adding to a water bottle; Sport Rub, a CBD post-activity rub for aches and pains; and Quick Hit, a CBD gummy with vitamin B12 under the Equilibrium Bio brand. In addition, it offers Skin Structure, a facial formula topically applied to enhance skin's radiance and youthfulness; Eye Recover that helps the eye skin ward off free radicals, as well as helping to protect against sun damage; Glossy Lip Recover, which moisturizes and nourishes lips; Skin Designer that stimulates cell regeneration while minimizing age spots; Vitamin Absolute, a moisturizing facial oil; and Absolute Recover, a formulation that allows the infused bioactive compounds to be delivered directly to the desired areas of inflammation, pain, and other skin ailments under the MaXXa brand. In addition, it is developing ALID 10 and ALID 11, a pharma product, which is in Phase I clinical trial for treating post-traumatic stress disorder. The company was incorporated in 2013 and is headquartered in Kelowna, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑08 | 2022‑08 | 2021‑08 | 2020‑08 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||